Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Ezra M. Chung"'
Autor:
Kyung Hyeon Lee, Nadia Fazal Ali, Soo Hyeon Lee, Zhimin Zhang, Marie Burdick, Zachary J. Beaulac, Greg Petruncio, Linxia Li, Jiangdong Xiang, Ezra M. Chung, Kenneth W. Foreman, Schroeder M. Noble, Yun M. Shim, Mikell Paige
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract The aminopeptidase activity (AP) of the leukotriene A4 hydrolase (LTA4H) enzyme has emerged as a therapeutic target to modulate host immunity. Initial reports focused on the benefits of augmenting the LTA4H AP activity and clearing its putat
Externí odkaz:
https://doaj.org/article/5e035599853c418c91141324ae6d3acc
Autor:
Kyung Hyeon, Lee, Nadia Fazal, Ali, Soo Hyeon, Lee, Zhimin, Zhang, Marie, Burdick, Zachary J, Beaulac, Greg, Petruncio, Linxia, Li, Jiangdong, Xiang, Ezra M, Chung, Kenneth W, Foreman, Schroeder M, Noble, Yun M, Shim, Mikell, Paige
Publikováno v:
Scientific reports. 12(1)
The aminopeptidase activity (AP) of the leukotriene A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a53b0c62b6a8ce1f296d547c3980c676
https://pubmed.ncbi.nlm.nih.gov/35676292
https://pubmed.ncbi.nlm.nih.gov/35676292
Publikováno v:
Cancer Research. 82:5318-5318
Butyrophilin 1A1 (BTN1A1) is a novel immune checkpoint protein that exhibits an expression pattern mutually exclusive to that of PD-1/PD-L1 and may represent a promising therapeutic target for tumors that are anti-PD-1/PD-L1 antibody refractory. BTN1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a9e96b0bfcc38d93ae180051edc0149b
https://doi.org/10.1158/1538-7445.am2022-5318
https://doi.org/10.1158/1538-7445.am2022-5318
Publikováno v:
Molecular Cancer Therapeutics. 20:LBA019-LBA019
Butyrophilin (BTN) proteins are members of the B7 immunoglobulin superfamily and exhibit well-characterized immunomodulatory functions in mammals. We have recently identified BTN1A1 as an immune checkpoint protein prominently upregulated in response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::95463dc4373ef5c842a258168588bd39
https://doi.org/10.1158/1535-7163.targ-21-lba019
https://doi.org/10.1158/1535-7163.targ-21-lba019
Abstract 1643: BTN1A1: a novel immune checkpoint for cancer immunotherapy beyond the PD-1/PD-L1 axis
Autor:
Young-Ok You, Yong-Sik Bong, Ezra M. Chung, Young-Joon Lee, Stephen S. Yoo, Andrew H. Park, Hyunjin Jung, Steven H. Lin, Young-Seung Kim, Amrish Sharma
Publikováno v:
Cancer Research. 81:1643-1643
Cancer immunotherapy is an effective treatment against individuals with late-stage cancer forms. The PD-1/PD-LI axis is a main therapeutic target used in clinical settings, but only 15-20% of cancer patients are responsive. Thus, there is an urgent u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5597724238b7663363d7c5021f25afa7
https://doi.org/10.1158/1538-7445.am2021-1643
https://doi.org/10.1158/1538-7445.am2021-1643
Autor:
Jielin Liu, Li Chuan Chan, Kay-Hooi Khoo, Yi Yang, Kim Yong Soo, Yun-Ju Lai, Jong Ho Cha, Heng Huan Lee, Stephen S. Yoo, Andrew H. Park, Chia Wei Li, Ri Yao Yang, Jennifer L. Hsu, Mien Chie Hung, Jun Yao, Jung-Mao Hsu, Linlin Sun, Yu Han Wang, Ezra M. Chung, Yufan Qiu
Publikováno v:
Cancer Res
Immunotherapies targeting programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) immune checkpoints represent a major breakthrough in cancer treatment. PD-1 is an inhibitory receptor expressed on the surface of activated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5e3d1c0daee6ffacdc25d9a0f08fa0a
https://pubmed.ncbi.nlm.nih.gov/32156778
https://pubmed.ncbi.nlm.nih.gov/32156778
Autor:
Jung-Mao Hsu, Yufan Qiu, Yu-Han Wang, Yi Yang, Kay-Hooi Khoo, Yongsoo Kim, Mien Chie Hung, Jong Ho Cha, Chia Wei Li, Linlin Sun, Jennifer L. Hsu, Li Chuan Chan, Andrew H. Park, Yun-Ju Lai, Ezra M. Chung, Stephen S. Yoo, Ri Yao Yang, Jielin Liu, Heng Huan Lee
Publikováno v:
Cancer Research. 80:6527-6527
Immunotherapy targeting programmed cell death protein 1 (PD-1) and programmed cell death 1 ligand 1 (PD-L1) immune checkpoints represents a major breakthrough in cancer treatment. PD-1 is an inhibitory receptor expressed on the surface of activated T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac5ecbfed22d8abb781129a06d0b5b41
https://doi.org/10.1158/1538-7445.am2020-6527
https://doi.org/10.1158/1538-7445.am2020-6527
Autor:
Kay-Hooi Khoo, Shih Shin Chang, Kim Yong Soo, Chia Wei Li, Taewan Kim, Ezra M. Chung, Jennifer L. Hsu, Jong Ho Cha, Aysegul A. Sahin, Yen-Liang Liu, Andrew H. Park, Chu Wei Kuo, Jun Yao, Gabriel N. Hortobagyi, Weiya Xia, Tzu Hsuan Huang, Chao Kai Chou, Hirohito Yamaguchi, Yun Wu, Evan P. Perillo, Jung Mao Hsu, Hsin-Chih Yeh, Stephen S. Yoo, Li Chuan Chan, Andrew K. Dunn, Seung Oe Lim, Heng Huan Lee, Mien Chie Hung
Publikováno v:
Cancer cell. 33(2)
Summary Protein glycosylation provides proteomic diversity in regulating protein localization, stability, and activity; it remains largely unknown whether the sugar moiety contributes to immunosuppression. In the study of immune receptor glycosylatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27c9cfcdd8b9221d3c60d7004638e613
https://pubmed.ncbi.nlm.nih.gov/29438689
https://pubmed.ncbi.nlm.nih.gov/29438689
Publikováno v:
BMC Microbiology
Background Our group has developed a new process for isolating and identifying novel cationic antimicrobial peptides from small amounts of biological samples. Previously, we identified several active antimicrobial peptides from 100 μl of plasma from
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0e7e191605cf42167d25dc9400956e9
http://europepmc.org/articles/PMC4992317
http://europepmc.org/articles/PMC4992317
Publikováno v:
NPJ Biofilms and Microbiomes
npj Biofilms and Microbiomes, Vol 3, Iss 1, Pp 1-13 (2017)
npj Biofilms and Microbiomes, Vol 3, Iss 1, Pp 1-13 (2017)
Cationic antimicrobial peptides are multifunctional molecules that have a high potential as therapeutic agents. We have identified a histone H1-derived peptide from the Komodo dragon (Varanus komodoensis), called VK25. Using this peptide as inspirati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76b47c25ae475c796ae693dcdbf93759
https://pubmed.ncbi.nlm.nih.gov/28649410
https://pubmed.ncbi.nlm.nih.gov/28649410